Feb-27-15 Antibe Therapeutics Reports Q3 2015 Interim Financial and Operating Results and Director Resignation
Feb-04-15 Antibe Therapeutics Announces No Material Change
Jan-16-15 Antibe Therapeutics Suspends its Phase I Clinical Trial Due to Safety Concerns
Dec-18-14 Antibe Therapeutics Announces Appointment of Canadian Rheumatologist J. Carter Thorne to its Clinical Advisory Board
Dec-16-14 Antibe Therapeutics Announces Appointment of US-Based Investor Relations Consultant
Nov-28-14 Antibe Therapeutics Reports Q2 2015 Interim Financial and Operating Results
Nov-25-14 Antibe Therapeutics Provides Update on its Acute Pain Drug ATB-352
Oct-06-14 Antibe Therapeutics Completes Single Ascending Dose Portion of ATB-346 Phase I Program
Oct-03-14 Antibe Therapeutics Reports on Results of AGM Voting
Sep-15-14 Antibe Therapeutics Commences Trading on the US OTCQX Marketplace
Sep-05-14 Antibe Therapeutics’ Founder Leads Study Identifying a Novel Mechanism for Treating Inflammatory Bowel Disease
Aug-24-14 Antibe Therapeutics Reports Q1 2015 Interim Financial and Operating Results
Jul-28-14 Antibe Therapeutics Reports Year-End Financial and Operating Results
Jul-17-14 Antibe Therapeutics Announces the Formation of its Clinical Advisory Board
Jun-26-14 Antibe Therapeutics Announces First Human Dose of ATB-346 in Phase I Clinical Trial
Jun-19-14 Antibe Therapeutics Receives Approval from Health Canada to Begin Human Clinical Testing
May-21-14 Antibe Therapeutics Announces Submission of Clinical Trial Application to Health Canada for ATB-346
May-12-14 Antibe Therapeutics Announces Addition to its Board of Directors and Grant of Options
May-05-14 CEO Letter to Shareholders
Apr-28-14 Antibe Therapeutics Completes Final Closing of Non-Brokered Private Placement Bringing Total Proceeds to $4,259,958